One of the 100 limited-edition framed certificates we're sending to the first group of companies that signed up for an Enterprise plan

Un­lock the full End­points ex­pe­ri­ence for your com­pa­ny — and sup­port our mis­sion of in­de­pen­dent bio­phar­ma re­port­ing

I want to give read­ers a quick up­date on the most im­por­tant part of our busi­ness mod­el — pre­mi­um sub­scrip­tions. We have some cru­cial fi­nan­cial goals we hope to achieve by the end of the year, and the team here in Lawrence is ready to ship some swag to kick off this lim­it­ed De­cem­ber pro­mo­tion.

We of­fer two pre­mi­um plans — En­ter­prise for com­pa­nies ($1,000/year, un­lim­it­ed peo­ple), and In­sid­er for in­di­vid­u­als ($200/year). This month of De­cem­ber will be the last chance to en­roll at the orig­i­nal rates — which have re­mained flat since we launched them in 2017.

Both plans un­lock ac­cess to our en­tire pre­mi­um con­tent li­brary like 100 top VCs in bio­phar­ma, Re­al World End­points: the brave new world com­ing in build­ing fran­chise ther­a­pies, and the top 20 pre­clin­i­cal biotech deals, and much more. You get ac­cess to tools like down­load­ing ar­ti­cles to PDF, our VIP sup­port team, and most of all, you’re di­rect­ly fund­ing the fu­ture de­vel­op­ment of End­points. These plans have been the rea­son we’ve been able to make new ed­i­to­r­i­al hires, with more to come. And we’re adding new ben­e­fits next year: paid sub­scribers will have ex­clu­sive ac­cess to watch our an­nu­al event at JP Mor­gan live at no ad­di­tion­al cost.

  • In­di­vid­u­als — sign-up for In­sid­er. All of the ben­e­fits above plus the op­tion to dis­able all ad­ver­tis­ing across web and email, and dis­count­ed tick­ets to End­points events. $200/year, end­ing soon.
  • Com­pa­nies — sign-up for En­ter­prise. Cov­ers every­one at your or­ga­ni­za­tion for $1,000/year. In­cludes a reprint li­cense to re­pur­pose and dis­trib­ute End­points con­tent in­ter­nal­ly. All em­ploy­ees will al­so be­gin to see a new “Your com­pa­ny sup­ports in­de­pen­dent jour­nal­ism” ban­ner in their dai­ly email re­ports.

By up­grad­ing, you’re di­rect­ly sup­port­ing in­de­pen­dent bio­phar­ma re­port­ing, and we’re look­ing for ways big and small to help pro­mote that among our read­ers. And that’s where the swag comes in.

The next 100 In­sid­er ac­counts to sign-up will re­ceive these vinyl stick­ers — 4 in a se­ries — that our stu­dio cre­at­ed.

And the next new 25 En­ter­prise sub­scribers will get stick­ers plus one of these amaz­ing­ly com­fort­able hood­ies. (Our sup­port team will reach out to get your pre­ferred size!)

Fi­nal­ly, the stu­dio cre­at­ed 100 lim­it­ed edi­tion framed cer­tifi­cates in hon­or of the very first batch of com­pa­nies who signed up for the En­ter­prise plan back when we launched it in the sum­mer of 2017. You can see a copy of what they look like at the top of this post.

These sub­scrip­tion plans helped End­points scale up to where we are to­day: serv­ing 400,000 unique read­ers per month on the web and near­ly 70,000 bio­phar­ma pros dai­ly by email, sup­port­ed by a glob­al­ly dis­trib­uted work­force, 15-strong and grow­ing, head­quar­tered in Lawrence, Kansas.

And we have big plans for 2020 — new cov­er­age ar­eas, prod­ucts, and deep­er re­port­ing on the peo­ple and trends that shape the bio­phar­ma world. The best way to help us get there is up­grad­ing to In­sid­er or En­ter­prise.

If you de­pend on End­points, it’s a sure bet we de­pend on you too. So please join us now be­fore De­cem­ber 31 while our orig­i­nal In­sid­er and En­ter­prise rates re­main. You can al­ways con­tact our help­ful sup­port team at help@end­pointsnews.com or by vis­it­ing your Read­er Pro­file.

In­side Track: Be­hind the Scenes of a Ma­jor Biotech SPAC

Dr. David Hung and Michelle Doig are no strangers to the SPAC phenomenon. As Founder and CEO of Nuvation Bio, a biotech company tackling some of the greatest unmet needs in oncology, Dr. Hung recently took the company public in one of this year’s biggest SPAC related deals. And as Partner at Omega Funds, Doig not only led and syndicated Nuvation Bio’s Series A, but is now also President of the newly formed, Omega-sponsored, Omega Alpha SPAC (Nasdaq: OMEG; oversubscribed $138m IPO priced January 6, 2021).

Barry Greene, Sage CEO

UP­DAT­ED: Sage's sec­ond chance at de­pres­sion hits the PhI­II pri­ma­ry, but ques­tions re­main over dura­bil­i­ty, side ef­fects

Looking to make a comeback after a big Phase III flop, Sage Therapeutics revealed data they believe could change the entire depression treatment landscape, given the vast array of failures in the field. But some results are spooking investors, sending Sage $SAGE shares down early Tuesday.

First, the primary: Sage and Biogen reported Phase III data for once-daily zuranolone Tuesday morning, saying the experimental drug hit its primary endpoint by spurring a statistically significant change from baseline in the 17-item Hamilton Rating Scale for Depression total score. After 15 days, patients in the drug arm saw an average change of -14.1 points, compared to -12.3 on placebo.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 109,500+ biopharma pros reading Endpoints daily — and it's free.

CEO Harith Rajagopalan (Fractyl)

Af­ter a decade in the type 2 di­a­betes game, Fractyl Lab­o­ra­to­ries recharges with a fresh $100M and a new name

Harith Rajagopalan compared the way type 2 diabetes is managed to sticking your fingers in a dam that’s leaking from a number of places.

You can take drugs to lower your blood sugar, cholesterol, or blood pressure, but you’re not addressing what he says is the core issue — the metabolic abnormality that causes the disease.

“We’re so busy plugging the holes in the dam, we don’t have time to see that the whole infrastructure is at risk,” he said. “That infrastructure is a full-body systemic metabolic abnormality called metabolic syndrome, that we’re ignoring while we’re so busy trying to treat all of the individual symptoms of the condition.”

Bio­gen sig­nals a big PhI­II fail­ure as the lead gene ther­a­py in their $800M Night­star buy­out goes down in flames

That $800 million buyout of Nightstar has turned into a bust for Biogen as the lead therapy in the deal failed a pivotal study, signaling a severe setback for the biotech’s ambitions in gene therapies.

The big biotech put out the word after the market closed on Monday that the gene therapy they picked up in the deal for a degenerative blindness called choroideremia failed the Phase III study, just a month after their #2 drug in the deal also flopped in a mid-stage study.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 109,500+ biopharma pros reading Endpoints daily — and it's free.

Hal Barron, GSK R&D chief (Endpoints News)

Hal Bar­ron gam­bles $625M cash on high-wire TIG­IT act, throw­ing Glax­o­SmithK­line in­to heat­ed race and com­plet­ing next-gen I/O trin­i­ty

Count Hal Barron and GlaxoSmithKline in for the TIGIT fight.

The stakes are as high as the risks: While a growing pack of Big Pharma rivals is lending credence to the hypothesis that TIGIT will be the next big immune checkpoint and cancer drug target, the first clinical trials have shown response rates that can be described as modest at best. But Barron’s bet is on the whole “axis” that the receptor sits on, with an eye on testing its new anti-TIGIT antibody not just in combo with PD-1 but also in triplets.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 109,500+ biopharma pros reading Endpoints daily — and it's free.

Michel Sade­lain puts his name and new cell en­gi­neer­ing tech be­hind 'ag­nos­tic' CAR-T start­up chas­ing epi­ge­net­ic anti­gens

It felt natural for Alain Maiore and Sebastian Amigorena to bring in Michel Sadelain as a co-founder of Mnemo Therapeutics. A CAR-T pioneer, Sadelain had been involved as an advisor since the early days — enthusiastic about Amigorena’s work in a genetic knockout that could enhance T cell memory and a new class of potential targets he’s discovered — and could introduce some well-known technologies to the toolbox. So they got the initial cash from Sofinnova Partners to plant roots in Paris and New York in early 2019; within a few months, they began to see more clearly just what the antigen discovery platform might unlock.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 109,500+ biopharma pros reading Endpoints daily — and it's free.

Lynn Fitch, Mississippi Attorney General (Rogelio V. Solis/AP Images)

Mis­sis­sip­pi sues Eli Lil­ly, Sanofi and No­vo over in­sulin prices as in­ter­change­able biosim­i­lars may ar­rive soon

Mississippi Attorney General Lynn Fitch last week sued the top three insulin manufacturers, which collectively cover almost the entire US insulin market, alleging that they’ve colluded to raise their prices in lockstep, and in some cases by more than 1,000% for drugs that are decades old.

“Because of Manufacturer Defendants’ collusive price increases, nearly a century after the discovery of insulin, diabetes medications have become unaffordable for many diabetics,” the lawsuit says.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 109,500+ biopharma pros reading Endpoints daily — and it's free.

Andrew Hopkins, Exscientia CEO

Ex­sci­en­tia spends Soft­Bank's cash in bid to edge out AI ri­vals

Exscientia is sprinting to win the great AI biotech race.

The UK company, having long labored on small discovery deals with large pharmas, raised up to $525 million in a Series D led by the infamous Japanese conglomerate SoftBank in April and followed it up less than a month later with a Bristol Myers Squibb deal that paid $50 million cash and $1.2 billion in milestones.

Now, the Oxford spinout is splurging on a shiny new tool. On Monday they announced they purchased the three-year-old molecule-screening biotech Allcyte, a longtime collaborator, for $60.6 million in cash and stock.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 109,500+ biopharma pros reading Endpoints daily — and it's free.

As Covid-19 shifts the world's at­ten­tion to biotech, Noubar Afeyan's Flag­ship builds $3.4B fund to fu­el new in­ven­tions. Here's the plan

A little more than a year ago, Flagship Pioneering rolled out a monster fund with $1.1 billion in it to bankroll the platform companies they were creating inside their own labs. But it turns out, that was just the prelude to a much, much larger raise, as both current investors — who’ve been reaping the rewards of some booming biotech stocks — join in with new investors betting on more in the years to come.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.